PMID- 17922047
OWN - NLM
STAT- MEDLINE
DCOM- 20080219
LR  - 20211020
IS  - 1219-4956 (Print)
IS  - 1219-4956 (Linking)
VI  - 13
IP  - 3
DP  - 2007
TI  - Detection of bladder cancer from the urine using fluorescence in situ 
      hybridization technique.
PG  - 187-94
AB  - The authors report on their first experiences with the UroVysion fluorescence in 
      situ hybridization (FISH) kit developed for the detection of bladder cancer. This 
      new non-invasive diagnostic application of the FISH technique in the field of 
      urology was elaborated to replace cystoscopy. The special urine examination 
      method detects genetic alterations of the urothelial cells found in the urine, 
      using fluorescent directlabeled DNA probes binding to the peri-centromeric 
      regions of chromosomes 3, 7 and 17 as well as on the 9p21 locus. We aimed to 
      evaluate the utility of UroVysion test in the light of the histological 
      diagnosis. Urine samples from 43 bladder cancer patients and 12 patients with no 
      or benign alterations were studied using a new application of FISH technique: the 
      UroVysion reagent kit. The obtained FISH results were compared with the 
      histological findings of the transurethral surgical resection specimens. The 
      study rated the specificity and sensitivity of the technique 100% and 87%, 
      respectively. Therefore, the technique could well fit into the diagnostic process 
      of bladder carcinomas. Statistical analyses showed significant correlation 
      between tumor progression and the severity of the genetic alterations detected by 
      this FISH technique. Furthermore, positive correlation was found between tumor 
      grade and the proportion of tumor cells showing genetic abnormality. The 
      noninvasiveness, the robustness of evaluation and the high 
      specificity/sensitivity are all in favor of this technique. The disadvantages are 
      the higher costs of the technical background and the required future clinical 
      studies to determine whether this technique can replace cystoscopy.
FAU - Riesz, Peter
AU  - Riesz P
AD  - Department of Urology, Semmelweis University, Budapest, Hungary.
FAU - Lotz, Gabor
AU  - Lotz G
FAU - Paska, Csilla
AU  - Paska C
FAU - Szendroi, Attila
AU  - Szendroi A
FAU - Majoros, Attila
AU  - Majoros A
FAU - Nemeth, Zsuzsanna
AU  - Nemeth Z
FAU - Torzsok, Peter
AU  - Torzsok P
FAU - Szarvas, Tibor
AU  - Szarvas T
FAU - Kovalszky, Ilona
AU  - Kovalszky I
FAU - Schaff, Zsuzsa
AU  - Schaff Z
FAU - Romics, Imre
AU  - Romics I
FAU - Kiss, Andras
AU  - Kiss A
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071007
PL  - Switzerland
TA  - Pathol Oncol Res
JT  - Pathology oncology research : POR
JID - 9706087
SB  - IM
MH  - Case-Control Studies
MH  - Chromosome Aberrations
MH  - Chromosomes, Human, Pair 17
MH  - Chromosomes, Human, Pair 3
MH  - Chromosomes, Human, Pair 7
MH  - Cystoscopy/methods
MH  - Diagnosis, Differential
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Diseases/diagnosis/pathology
MH  - Urinary Bladder Neoplasms/*diagnosis/*pathology
MH  - Urine/*cytology
MH  - Urothelium/pathology
EDAT- 2007/10/09 09:00
MHDA- 2008/02/20 09:00
CRDT- 2007/10/09 09:00
PHST- 2007/02/05 00:00 [received]
PHST- 2007/09/05 00:00 [accepted]
PHST- 2007/10/09 09:00 [pubmed]
PHST- 2008/02/20 09:00 [medline]
PHST- 2007/10/09 09:00 [entrez]
AID - 10.1007/BF02893498 [doi]
PST - ppublish
SO  - Pathol Oncol Res. 2007;13(3):187-94. doi: 10.1007/BF02893498. Epub 2007 Oct 7.